Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

Warwick Medical School, University of Warwick, Coventry CV4 7AL, U.K. School of Biosciences, University of Sheffield, Sheffield S10 2TN, U.K. School of Mathematical and Physical Sciences, University ...

In this valuable study, the authors show the physiological response and molecular pathway mediating the effect of quinofumelin, a developed fungicide with an unknown mechanism. The authors present ...

A key concept emerging in the treatment of bladder cancer is the idea of broad immune potentiation. Traditional therapies like BCG may fail in some patients because they stimulate a narrow immune ...

Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to reduce neuroinflammation via a simple IV administration.

Allarity Therapeutics, Inc. has announced a research collaboration with the Indiana Biosciences Research Institute (IBRI) to enhance their understanding of stenoparib, a dual PARP and WNT pathway ...

Revised: This Reviewed Preprint has been revised by the authors in response to the previous round of peer review; the eLife assessment and the public reviews have been updated where necessary by the ...

SAN DIEGO and CALGARY, AB, April 24, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will present new ...

Currently, genetic diseases caused by mutations that introduce premature stop codons lack effective treatments. Aminoglycosides were the first compounds shown to promote read-through of these stop ...

PDL1V is a novel vedotin antibody drug-conjugate (ADC) currently in Phase I clinical development for advanced solid tumors as a monotherapy or in combination with pembrolizumab (NCT05208762). The ...